Hong Kong, September 1, 2021 / US News / – INSILICO Medicine announced that the Gray Matter reached project research and development cooperation, Gray Matter is a live biotechnology company, focusing on developing polypeptide-based therapies To fight against cognitive recession, aging related central nervous system diseases, as well as anti-aging. This cooperation is designed to use the English intelligent artificial intelligent drug research and development platform, and combine the close cooperation between Gray Matter and the English intelligent scientist team to accelerate the new target of cognitive recession related to aging.
The prevalence of mild cognitive impairment (MCI) is 60- The 64-year-old population is 6.7 percentage (equivalent to 1 person every 14 people), and the prevalence rate in the 80-84 population is significantly increased, which is 25.2% (equivalent to 1 person every 4 people) Those who have been diagnosed as mild cognitive disorders, with a probability of dementia with some form of dementia 3-5 times higher than that of ordinary people. With the aging of adult population, the increase in health care services, mild cognitive disorders are becoming a huge challenge in the public health circle, and we need to actively resolve. These very critical issues not only affect the elderly, but will also affect their families and friends they caregically.
The apeptide-based therapy is ideal for the development of a treatment plan for developing chronic diseases such as MCI. There is a large number of research data indicate that peptide drug revenue is more risky compared to gene therapy, cytotherapy, and other new therapies. In addition, the production of peptides also has more cost advantages compared to other new therapies.
Gray Matter Joint Founder and CEO Alexey Strygin said, “Our goal is to develop a new generation of safe and effective therapies, helping patients live longer and healthier in the case of cognition. We It was found that there was a significant synergistic effect between the proprietary peptide discovery engine Reptide and the intelligent intelligent target recognition platform of the intelligent intelligent target. This cooperation is to help the Gray Matter further reduced earlyThe cost and time of drug development. “
Dr. Alex Zhavoronkov, English, said,” Silicone intelligence is using machine learning, generating biology technology and composite data in the housing, etc., to iterate the latest target identification system, ” We are honored to cooperate with Gray Matter to target target recognition. Looking for peptide drug targets is an important way to find out, we are very excited to apply our frontier artificial intelligence technology platform to this challenging field. “
In August this year, the English intelligence has just nominated the second preclinical candidate compound for renal fibrosis.